EP4720047A1 - Amorphe und kristalline form von ozanimodhydrochlorid - Google Patents
Amorphe und kristalline form von ozanimodhydrochloridInfo
- Publication number
- EP4720047A1 EP4720047A1 EP24730931.3A EP24730931A EP4720047A1 EP 4720047 A1 EP4720047 A1 EP 4720047A1 EP 24730931 A EP24730931 A EP 24730931A EP 4720047 A1 EP4720047 A1 EP 4720047A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ozanimod hydrochloride
- ozanimod
- hydrochloride
- amorphous
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23382526 | 2023-05-31 | ||
| PCT/EP2024/064854 WO2024246174A1 (en) | 2023-05-31 | 2024-05-30 | Amorphous and crystalline form of ozanimod hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4720047A1 true EP4720047A1 (de) | 2026-04-08 |
Family
ID=86657651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24730931.3A Pending EP4720047A1 (de) | 2023-05-31 | 2024-05-30 | Amorphe und kristalline form von ozanimodhydrochlorid |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4720047A1 (de) |
| CN (1) | CN121194965A (de) |
| WO (1) | WO2024246174A1 (de) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE025984T2 (hu) | 2008-05-14 | 2016-05-30 | Scripps Research Inst | Szfingozin foszfát receptor új modulátorai |
| DK2365972T3 (en) | 2008-11-06 | 2015-01-19 | Vertex Pharma | Modulators of atp-binding cassette conveyors |
| KR101781233B1 (ko) | 2009-11-13 | 2017-09-22 | 셀진 인터내셔널 Ii 에스에이알엘 | 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법 |
| SI2498610T2 (sl) | 2009-11-13 | 2024-10-30 | Receptos Llc | Selektivni modulatorji receptorja sfingozin-1-fosfata in postopki kiralne sinteze |
| CN105130948A (zh) | 2010-04-22 | 2015-12-09 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
| FI3470400T3 (fi) * | 2016-06-14 | 2025-06-13 | Receptos Llc | Otsanimodin kidemuoto, sen hydrokloridin kidemuoto ja niiden valmistusmenetelmä |
| US10882830B2 (en) | 2016-09-14 | 2021-01-05 | Receptos Llc | Crystal form of ozanimod hydrochloride and processes for preparation therefor |
| CN108245487A (zh) | 2016-12-28 | 2018-07-06 | 宁波爱诺医药科技有限公司 | 一种无定型奥扎莫德或其药学上可接受的盐与药用辅料的固体分散体及其制备方法 |
| CN110612292A (zh) | 2017-04-07 | 2019-12-24 | 杭州领业医药科技有限公司 | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 |
| CN110944982A (zh) | 2017-08-31 | 2020-03-31 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| CN107840830A (zh) | 2017-09-20 | 2018-03-27 | 广东东阳光药业有限公司 | 盐酸奥扎莫德无水晶型i |
| WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
| EP3891133B1 (de) * | 2018-12-07 | 2023-06-07 | Synthon B.V. | Verbessertes verfahren zur herstellung von ozanimod |
| WO2020152718A1 (en) | 2019-01-25 | 2020-07-30 | Mylan Laboratories Limited | Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile |
| EP4126826A1 (de) | 2020-04-02 | 2023-02-08 | Synthon B.V. | Kristalline form von ozanimodhydrochlorid |
| WO2023152767A1 (en) * | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
-
2024
- 2024-05-30 WO PCT/EP2024/064854 patent/WO2024246174A1/en not_active Ceased
- 2024-05-30 EP EP24730931.3A patent/EP4720047A1/de active Pending
- 2024-05-30 CN CN202480034931.5A patent/CN121194965A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024246174A1 (en) | 2024-12-05 |
| CN121194965A (zh) | 2025-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10414741B2 (en) | Amorphous vortioxetine and salts thereof | |
| US9249134B2 (en) | Process for preparation of amorphous form of dasatinib | |
| WO2011095059A1 (zh) | 达沙替尼多晶型物及其制备方法和药物组合物 | |
| US9351957B2 (en) | Amorphous form of apremilast | |
| JP2020513023A (ja) | ルマテペロンｐ−トシラートの非晶質形態および固体分散体 | |
| CZ2016391A3 (cs) | Farmaceutická formulace olaparibu | |
| EA024991B1 (ru) | Полиморфная форма питавастатина кальция | |
| JP2025074350A (ja) | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 | |
| US7271269B2 (en) | Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods | |
| CA2952627C (en) | Anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole | |
| WO2024246174A1 (en) | Amorphous and crystalline form of ozanimod hydrochloride | |
| EP2474529B1 (de) | Kristallinformen von aktiven pharmazeutischen Inhaltsstoffen | |
| WO2016193994A1 (en) | Amorphous selexipag and process for preparation thereof | |
| EP2832723B1 (de) | Stabilisierte amorphe Formen von Saxagliptin | |
| EP4486727B1 (de) | Kristalline form von darolutamid | |
| WO2011139414A2 (en) | Dexlansoprazole polymorphic forms | |
| EP4137133A1 (de) | Kristalline form von avacopan | |
| CA2591670A1 (en) | Process of preparing ziprasidone mesylate | |
| HK1237761A1 (en) | Solid forms of a pharmaceutically active substance | |
| HK1237761A (en) | Solid forms of a pharmaceutically active substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20260102 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |